SHL Telemedicine is launching a membership programme in the US for its SmartHeart device to treat post-myocardial infarction (MI) patients.
SmartHeart is a battery-powered device with a 12-lead electrocardiogram (ECG) and rhythm strip, with ECG results transmitted via Bluetooth directly to a healthcare professional. The device received 510(K) clearance in 2011 from the US Food and Drug Administration (FDA) for remote patient monitoring.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The membership plan offers around-the-clock interpretation by cardiologists and access to medical professionals for consultations. According to SHL Telemedicine, patients are offered a variety of private-pay subscription options, depending on the individual needs of each patient.
In the announcement accompanying the launch, SHL Telemedicine CEO Erez Nachtomy said: “This service transcends mere technological innovation; it represents a significant advancement in delivering care and reassurance into the lives of individuals, transforming access to cardiac care, making it less daunting and more approachable for all.”
Clinical trial data for the device was presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 on 20 September, from the HELP-MI and TELE-ACS trials. The data from the TELE-ACS trial showed that there was a 27.5% decrease in emergency room visits for post-MI patients upon using the SmartHeart device. Hospital readmission rates were decreased by 55% in this patient group.
The HELP-ME trial data showed that the emergency room visits and the hospital readmission rates were zero for post-MI patients upon using the SmartHeart device.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to a report on GlobalData’s Medical Device Intelligence Center, the remote patient monitoring market will reach $760m by 2030.
SHL Telemedicine generated $29m in total revenue in the first half of this year, according to the company’s H1 2023 report.
Another player in the industry is HeartBeam, which was awarded a third US patent for its 12-lead extended wear patch earlier this month. The device is an extended wear patch for identifying heart attacks and cardiac arrhythmias, centred around the company’s 3D-vector electrocardiogram (VECG) platform.
